Chemistry:Abafungin
Abafungin (INN) is a broad-spectrum arylguanidines-class antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.[1]
Abasol is a topical cream formulation of abafungin by York Pharma.[2]
History
Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H2-antagonists related to famotidine, resulted in the discovery of its antifungal properties.[3]
Its development seems to have been discontinued in 2009.[4]
Mechanism of action
Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[3]
In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[5]
Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[6]
References
- ↑ "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy 54 (4): 245–259. 2008. doi:10.1159/000142334. PMID 18587237.
- ↑ "Regulatory Update – Abasol". York Pharma. http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf.
- ↑ 3.0 3.1 "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy 54 (4): 245–259. August 2008. doi:10.1159/000142334. PMID 18587237.
- ↑ "Abafungin". AdisInsight. https://adisinsight.springer.com/drugs/800022887.
- ↑ "ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis". Kidney International 48 (6): 1778–1791. December 1995. doi:10.1038/ki.1995.476. PMID 8587237.
- ↑ (in de) Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten. Österreichische Apothekerkammer (Austrian Chamber of Pharmacists). March 2009. p. 103.
External links
 |  |
